Fibrocalculous Pancreatic Diabetes (FCPD): A Rare Type of Pancreatogenic Diabetes

Authors

  • Ega Caesaria Pratama Putra Endocrinology, Metabolic and Diabetes Division Sebelas Maret University / Moewardi General Hospital, Surakarta, Indonesia Author
  • Eva Niamuzisilawati Endocrinology, Metabolic and Diabetes Division Sebelas Maret University / Moewardi General Hospital, Surakarta, Indonesia Author
  • Yulia Sekarsari Endocrinology, Metabolic and Diabetes Division Sebelas Maret University / Moewardi General Hospital, Surakarta, Indonesia Author
  • Brilliant Van Fitof Songso Rhomado Endocrinology, Metabolic and Diabetes Division Sebelas Maret University / Moewardi General Hospital, Surakarta, Indonesia Author
  • Supriyanto Kartodarsono Endocrinology, Metabolic and Diabetes Division Sebelas Maret University / Moewardi General Hospital, Surakarta, Indonesia Author

DOI:

https://doi.org/10.66266/inajemd.v2i2.68

Keywords:

Fibrocalculous Pancreatic Diabetes, Diabetes Mellitus, Chronic Pancreatitis

Abstract

Background: FCPD is a rare form of secondary diabetes. FCPD is mainly found in the tropical region; it is characterized by diabetes, chronic abdominal pain, calcification of the pancreas, and steatorrhea. The Incidence of FCPD is often misdiagnosed with type 2 or type 1 diabetes mellitus.
Case Illustration: A 46-year-old man came with chief complaints of chronic abdominal pain. Abdominal radiography showed calcification in the pancreas. The patient was malnourished. Abdominal X-ray revealed pancreatic calcification, which was confirmed by an abdominal MSCT scan. C-Peptide decreased with an intermediate degree. The patient was given supportive therapy,
and insulin was given to control his diabetes.
Discussion: FCPD is a morphological pancreas change caused by chronic tropical pancreatitis. The aetiology of chronic tropical pancreatitis is unknown. FCPD can be diagnosed by history taking and supporting examinations such as abdominal X-ray examination, ultrasound and abdominal CT Scan. C-peptide was examined to assess the function of pancreatic beta cells. The primary treatment for FCPD is insulin therapy; metformin or Sulfonylureas can be used in the early phase of diabetes. In reducing pain, non-steroidal analgesics are used as an option. The use of pancreatic enzyme supplementation can improve the nutritional status of patients.
Conclusion. FCPD is a rare case, occurring mainly in tropical countries and in people who are malnourished. The primary treatment for FCPD is insulin therapy.

Downloads

Download data is not yet available.

References

1. Kumaran S, Unnikrishnan AG. Fibrocalculous

pancreatic diabetes. J Diabetes Complications.

2021;35(1):1–7.

2. Aiswarya Y, Shivaprasad C, Anish K, Sridevi

A, Anupam B, Amit G. Assessment of insulin

sensitivity and secretion in patients with

fibrocalculous pancreatic diabetes. Diabetes,

Metab Syndr Obes Targets Ther. 2019;12:779–88.

3. Praveen G, Mohan V. Fibrocalculous

pancreatic diabetes — current scenario in

developing countries. Int J Diabetes Dev Ctries.

2018;38(2):131–2.

4. Unnikrishnan R, Mohan V. Fibrocalculous

pancreatic diabetes (FCPD). Acta Diabetol.

2015;52(1):1–9.

5. Barman KK, Premalatha G, Mohan V. Tropical

chronic pancreatitis. Postgr Med J. 2003;79:606–

15.

6. Chowdhury Z, Mcdermott MF, Davey S,

Hassan Z, Sinnott PJ, Hemmatpour SK. Genetic

susceptibility to fibrocalculous pancreatic

diabetes in Bangladeshi subjects: a family study.

Genes Immun. 2002;3:5–8.

7. Ralapanawa DMP, Jayawickreme K poornima,

Ekanayake EM. Fibrocalculous pancreatic

diabetes : a case report. BMC Res Notes.

2015;8:175.

8. Shivaprasad C, Anish K, Aiswarya Y, Atluri S,

Rakesh B, Anupam B, et al. A comparative

study of the clinical profile of fibrocalculous

pancreatic diabetes and type 2 diabetes mellitus.

Diabetes Metab Syndr Clin Res Rev [Internet].

2019;13(2):1511–6. Available from: https://doi.

org/10.1016/j.dsx.2019.03.003

9. Singh V, Tandon MS. Fibrocalculous Pancreatic

Diabetes in a Young Female : A Case Report from

South Gujarat. J Diabetol. 2019;10:140–2.

10. Bhat J, Bhat MH, Misgar R, Bashir M, Wani

A, Masoodi S, et al. The clinical spectrum of

fibrocalculous pancreatic diabetes in Kashmir

valley and comparative study of the clinical

profile of fibrocalculous pancreatic diabetes

and type 2 diabetes mellitus. Indian J Endocrinol

Metab. 2019;23(5):580–4.

11. Dasgupta R, Naik D, Thomas N. Emerging

concepts in the pathogenesis of diabetes in

fibrocalculous pancreatic diabetes. J Diabetes.

2015;7(6):754–61.

12. Xia F, Zhou W, Wang B, Hu Y. Non-tropical

fibrocalculous pancreatic diabetes: case reports

and review of recent literature. J Int Med Res.

2020;48(7).

13. Bavuma C, Sahabandu D, Musafiri S, Danquah I,

McQuillan R, Wild S. Atypical forms of diabetes

mellitus in Africans and other non-European

ethnic populations in low- and middle-income

countries: a systematic literature review. J Glob

Health. 2019;9(2):020401.

14. Ghosh I, Mukhopadhyay P, Das K, Anne M

B, Ali Mondal S, Basu M, et al. Incretins in

fibrocalculous pancreatic diabetes: A unique

subtype of pancreatogenic diabetes. J Diabetes.

2020;1–6.

Downloads

Published

01-12-2025

How to Cite

1.
Ega Caesaria Pratama Putra, Eva Niamuzisilawati, Yulia Sekarsari, Brilliant Van Fitof Songso Rhomado, Supriyanto Kartodarsono. Fibrocalculous Pancreatic Diabetes (FCPD): A Rare Type of Pancreatogenic Diabetes. InaJEMD [Internet]. 2025 Dec. 1 [cited 2026 Apr. 19];2(2):82-6. Available from: https://inajemd.pbperkeni.or.id/index.php/journal/article/view/vol2no2-12

Similar Articles

1-10 of 39

You may also start an advanced similarity search for this article.